# In-vivo Regulatory T Cell Enhancement With Cyclophosphamide and Sirolimus

> **NCT01453140** · PHASE1,PHASE2 · TERMINATED · sponsor: **Hackensack Meridian Health** · enrollment: 3 (actual)

## Conditions studied

- Graft Versus Host Disease

## Interventions

- **DRUG:** Cyclophosphamide and Sirolimus
- **DRUG:** Low dose IL-2 with Cytoxan + Sirolimus
- **DRUG:** Low dose IL-2, low dose Vidaza, cyclophosphamide & Sirolimus
- **DRUG:** Cyclophosphamide and Sirolimus
- **DRUG:** Low dose IL-2 with Cytoxan + Sirolimus
- **DRUG:** Low dose IL-2, Vidaza, Cytoxan & Sirolimus

## Key facts

- **NCT ID:** NCT01453140
- **Lead sponsor:** Hackensack Meridian Health
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-08
- **Primary completion:** 2012-03
- **Final completion:** 2012-07
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Dose Limiting Toxicities
- **Last updated:** 2026-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01453140

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01453140, "In-vivo Regulatory T Cell Enhancement With Cyclophosphamide and Sirolimus". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01453140. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*